Endometrial Cancer Trial, Recruiting NCT06038032 Sponsor: University of Alberta Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT06038032
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years old or older
  • People who have been diagnosed with a specific type of uterine cancer called low-grade endometrioid adenocarcinoma, at stages I to III (using FIGO 2009 staging)
  • People who finished surgery and any follow-up cancer treatment between 1 month and 10 years ago
  • People with a Body Mass Index (BMI) between 25 and 45 kg/m²
  • People who are willing and able to follow the study's activities and check-ins throughout the trial
  • People who show a readiness to work toward a healthier weight, as measured by a questionnaire
  • People who have a smartphone that works with the Fitbit app, with internet access and Bluetooth
  • People who can speak, read, and understand English

Who may not be able to join:

  • People whose uterine cancer has come back (in the same area or spread elsewhere) or has spread to other parts of the body
  • People who have an abnormal p53 gene result combined with a stage III or IV cancer diagnosis (confirm with trial site)
  • People whose weight has gone up or down by more than 5 kg in the past 3 months
  • People who have surgery planned within the next 6 months
  • People who have previously had weight-loss (bariatric) surgery
  • People with a thyroid condition that is not well controlled
  • People with Type 1 diabetes
  • People with Type 2 diabetes whose blood sugar levels are poorly controlled (HbA1c above 10%), or who are currently taking insulin, sulfonylureas, or GLP-1 medications for diabetes
  • People currently taking corticosteroid medications (a type of steroid)
  • People currently taking prescription weight-loss medications
  • People who currently smoke in any form, including cigarettes, e-cigarettes, vaping, or marijuana
  • People who are already doing more than 90 minutes per week of moderate-intensity aerobic exercise on average over the past 3 months
  • People for whom exercise or exercise testing may pose a safety risk, based on a health screening questionnaire and heart health assessment (confirm with trial site)
  • People with physical or mobility limitations that would prevent them from doing physical activity
  • People who have been following a structured low-calorie diet, a meal replacement program, a weight-loss meal plan, intermittent fasting, or a high-fat diet in the past 3 months — or people who have been following a vegan diet for less than two years
  • People with a history of an eating disorder that was diagnosed by a doctor
  • People who plan to be away for more than 2 weeks in a row during the study and would not be able to follow the study requirements during that time
  • People with active problems related to substance use, including alcohol, cannabis, or other drugs
  • People for whom a DXA scan or MRI scan is not safe (for example, those with a pacemaker or who are pregnant)
  • People who are unable to take part in phone or video sessions due to significant hearing or vision difficulties
  • People who are unable to follow the study requirements — for example, those who cannot commit to scheduled group video sessions, have very limited internet access, are not willing to use the study's online platform, have been advised by a health professional not to lose weight or reduce food intake, or who have cognitive impairment or dementia
  • People who are unable to travel to the study location
  • People who are unable to provide written consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Carla Prado, PhD, University of Alberta

Phone: 780-492-1151

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
25 March 2024
Est. completion
1 March 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change from baseline in waist circumference at week 16.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov